Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer

被引:0
作者
Hiroko Yamashita
Mariko Nishio
Tatsuya Toyama
Hiroshi Sugiura
Zhenhuan Zhang
Shunzo Kobayashi
Hirotaka Iwase
机构
[1] Nagoya City University Hospital,Breast and Endocrine Surgery
[2] Josai Municipal Hospital of Nagoya,undefined
来源
Breast Cancer Research | / 6卷
关键词
HER2; immunohistochemistry; invasive ductal carcinoma; p53;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 249 条
[1]  
Allred DC(1998)Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 155-168
[2]  
Harvey JM(1999)Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 3058-3063
[3]  
Berardo M(2000)Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 966-978
[4]  
Clark GM(1997)Clinical significance of bcl-2 gene expression in human breast cancer tissues Breast Cancer Res Treat 42 173-181
[5]  
Chang J(1993)Analysis of oncogenes and tumor suppressor genes in human breast cancer Jpn J Cancer Res 84 871-878
[6]  
Powles TJ(2000)The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2 Ann Oncol 11 647-663
[7]  
Allred DC(2001)Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast Breast Cancer 8 98-104
[8]  
Ashley SE(1992)Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers Jpn J Cancer Res 83 859-865
[9]  
Clark GM(1988)Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer Int J Cancer 42 842-845
[10]  
Makris A(1999)Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474-1481